The Efficiency of Sunitinib in Chinese Patients with Advanced Well-differentiated Pancreatic Neuroendocrine Tumor Abstract #1385

Introduction: Systemic therapies for advanced Pancreatic neuroendocrine tumors (pNETs) are various. Sunitinib has shown its efficiency in pNET in clinical trials. While the efficiency of sunitinib in Chinese pNETs has not reported yet.
Aim(s): To describe clinical outcomes of Chinese advanced pNETs patients(pts) treating with sunitinb, and compare the efficiency of sunitinb in first-line therapy and post-second line therapy in pNETs.
Materials and methods: Advanced pNET pts who accepted sunitinib treatment after disease progression were collected from April 2009 to May 2015. pts received sunitinib 37.5 mg/day or 25mg/d if intolerable, on a continuous daily dosing schedule. Data examined included clinicopathological characteristics and outcomes.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Heli Gao
Authors: Gao H, Cheng Y, Bai C M

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
#846 Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone
Introduction:
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Chunmei Bai
Authors: Ying H, Cheng Y, Sun Z, Xue H, ...
#1439 Sunitinib in the Treatment of Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm: A Multicenter Retrospective Study in China
Introduction: Sunitinib has shown activity against pancreatic neuroendocrine tumors(NEN) in a global phase III clinical trial.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Chen Jie
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca